BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares traded up 32.8% on Thursday . The company traded as high as $3.75 and last traded at $3.56, with a volume of 806,806 shares trading hands. The stock had previously closed at $2.68.

Separately, Maxim Group reiterated a “buy” rating and issued a $5.00 target price on shares of BrainStorm Cell Therapeutics in a research note on Saturday, June 4th.

The firm’s 50-day moving average price is $2.46 and its 200-day moving average price is $2.42. The company’s market cap is $66.41 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.15. On average, equities analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.58) EPS for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.